# STAT1

## Overview
STAT1 is a gene that encodes the protein signal transducer and activator of transcription 1, a critical component of the JAK-STAT signaling pathway. This protein functions as a transcription factor and is pivotal in mediating cellular responses to cytokines, particularly interferons, which are essential for immune defense mechanisms. STAT1 is activated through phosphorylation, which facilitates its dimerization and subsequent translocation to the nucleus, where it binds to specific DNA sequences to regulate gene expression. The protein is characterized by several domains, including a coiled-coil domain, a DNA-binding domain, and an SH2 domain, which are essential for its structural integrity and function (Chen1998Crystal). STAT1 plays a significant role in immune responses, cell growth inhibition, and apoptosis, and its dysregulation is associated with various clinical conditions, including chronic mucocutaneous candidiasis and increased susceptibility to infections (Najjar2010STAT1; Ott2023JAKs).

## Structure
STAT1 is a protein involved in the JAK-STAT signaling pathway, characterized by several distinct domains. The primary structure of STAT1 includes a coiled-coil domain, a DNA-binding domain, a linker domain, and an SH2 domain, with the DNA-binding domain exhibiting an immunoglobulin-like fold (Chen1998Crystal). The SH2 domain is crucial for dimerization and DNA binding, forming a C-shaped clamp around DNA when phosphorylated (Chen1998Crystal). 

The tertiary structure of STAT1 reveals a contiguous hydrophobic core formed by extensive interdomain interactions, with flexibility provided by a proline-rich linker region (Lim2006Structure). The quaternary structure involves dimerization, which is essential for its function. In its phosphorylated state, STAT1 forms a homodimer that binds to DNA, stabilized by interactions between the SH2 domain and the phosphorylated tail segment (Chen1998Crystal).

Post-translational modifications, such as phosphorylation at Tyr701, are critical for STAT1 activation and dimerization (Grönholm2012Structurefunction). Sumoylation at Lys703 has been shown to modulate its DNA-binding activity (Grönholm2012Structurefunction). STAT1 also exists in different isoforms, such as STAT1α and STAT1β, which may have distinct functional roles (Vinkemeier1996DNA).

## Function
STAT1 (signal transducer and activator of transcription 1) is a transcription factor that plays a crucial role in mediating cellular responses to interferons (IFNs) and other cytokines in healthy human cells. It is activated through phosphorylation, primarily at tyrosine 701 and serine 727, which is essential for its dimerization and subsequent activation of gene transcription (Najjar2010STAT1; Okada2020Human). Upon activation, STAT1 translocates to the nucleus, where it binds to specific DNA sequences, such as the gamma-activated sequence (GAS) and interferon-stimulated response element (ISRE), to regulate the expression of target genes involved in immune responses (Najjar2010STAT1; Stark1998HOW).

STAT1 is involved in the formation of complexes like ISGF3 and GAF, which are essential for activating transcription of genes that mediate immune responses, including antiviral defense (Chapgier2009A). It also plays a role in cell growth inhibition and apoptosis by regulating genes involved in cell cycle control and inducing proapoptotic genes (Najjar2010STAT1). In addition to its role in cytokine signaling, STAT1 is required for the constitutive expression of certain genes, affecting cellular processes in a stable and ongoing manner (Stark1998HOW).

## Clinical Significance
Mutations in the STAT1 gene can lead to a variety of clinical conditions, primarily due to its role in cytokine signaling. Gain-of-function (GOF) mutations in STAT1 are frequently associated with chronic mucocutaneous candidiasis (CMC), a condition characterized by persistent fungal infections of the skin, nails, and mucous membranes. These mutations also predispose individuals to recurrent bacterial and viral infections, autoimmune disorders, and an increased risk of certain cancers, such as squamous cell carcinomas (Zhang2021Clinical; Ott2023JAKs). GOF mutations can result in an IPEX-like syndrome, which includes autoimmune manifestations such as thyroid disease, cytopenia, and type I diabetes (Ott2023JAKs).

Loss-of-function (LOF) mutations in STAT1 can lead to increased susceptibility to mycobacterial and viral infections. These mutations are categorized into autosomal recessive complete, partial, and autosomal dominant deficiencies, with varying severity of clinical manifestations (Ott2023JAKs). Complete STAT1 deficiency results in severe viral infections and a high mortality rate unless treated with bone marrow transplants (Lorenzini2016STAT). Partial deficiencies, often due to missense mutations, lead to impaired immune responses, particularly against intracellular pathogens (Lorenzini2016STAT).

## Interactions
STAT1 interacts with various proteins and nucleic acids, playing a crucial role in cellular signaling pathways. It forms part of the ISGF-3 complex with STAT2 and the non-STAT protein p48, which is essential for binding to the ISRE (interferon-a stimulated response element) and mediating IFN-a responses. The interaction between STAT1 and p48 is weaker and more transient compared to STAT2, but it is critical for the induction of the ISG15 gene by IFN-a (Shuai2000Modulation).

STAT1 also interacts with the coactivators p300/CBP, which are involved in chromatin remodeling. This interaction occurs through two separate regions of STAT1: the NH2-terminal region interacts with the CREB-binding domain, and the COOH-terminal region interacts with the CH3 domain of p300/CBP. These interactions are crucial for STAT-mediated transcription (Shuai2000Modulation).

In the context of vitamin D signaling, STAT1 interacts with the vitamin D receptor (VDR), inhibiting VDR-RXR binding to the vitamin D response element and blocking 1,25D-induced transcription. This interaction is independent of STAT1 phosphorylation and enhances STAT1-mediated transcription by prolonging its activation (Vidal2002Stat1Vitamin).

The rabies virus P protein interacts with STAT1, inhibiting interferon signal transduction pathways by binding to the coiled-coil and DNA-binding domains of STAT1, thereby affecting IFN-induced responses (Vidy2005Rabies).


## References


[1. (Lorenzini2016STAT) Tiziana Lorenzini, Laura Dotta, Mauro Giacomelli, Donatella Vairo, and Raffaele Badolato. Stat mutations as program switchers: turning primary immunodeficiencies into autoimmune diseases. Journal of Leukocyte Biology, 101(1):29–38, November 2016. URL: http://dx.doi.org/10.1189/jlb.5ri0516-237rr, doi:10.1189/jlb.5ri0516-237rr. This article has 53 citations and is from a peer-reviewed journal.](https://doi.org/10.1189/jlb.5ri0516-237rr)

[2. (Lim2006Structure) Cheh Peng Lim and Xinmin Cao. Structure, function, and regulation of stat proteins. Molecular BioSystems, 2(11):536, 2006. URL: http://dx.doi.org/10.1039/b606246f, doi:10.1039/b606246f. This article has 255 citations and is from a peer-reviewed journal.](https://doi.org/10.1039/b606246f)

[3. (Chapgier2009A) Ariane Chapgier, Xiao-Fei Kong, Stéphanie Boisson-Dupuis, Emmanuelle Jouanguy, Diana Averbuch, Jacqueline Feinberg, Shen-Ying Zhang, Jacinta Bustamante, Guillaume Vogt, Julien Lejeune, Eleonore Mayola, Ludovic de Beaucoudrey, Laurent Abel, Dan Engelhard, and Jean-Laurent Casanova. A partial form of recessive stat1 deficiency in humans. Journal of Clinical Investigation, 119(6):1502–1514, June 2009. URL: http://dx.doi.org/10.1172/jci37083, doi:10.1172/jci37083. This article has 164 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci37083)

[4. (Okada2020Human) Satoshi Okada, Takaki Asano, Kunihiko Moriya, Stephanie Boisson-Dupuis, Masao Kobayashi, Jean-Laurent Casanova, and Anne Puel. Human stat1 gain-of-function heterozygous mutations: chronic mucocutaneous candidiasis and type i interferonopathy. Journal of Clinical Immunology, 40(8):1065–1081, August 2020. URL: http://dx.doi.org/10.1007/s10875-020-00847-x, doi:10.1007/s10875-020-00847-x. This article has 100 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1007/s10875-020-00847-x)

[5. (Najjar2010STAT1) Imen Najjar and Remi Fagard. Stat1 and pathogens, not a friendly relationship. Biochimie, 92(5):425–444, May 2010. URL: http://dx.doi.org/10.1016/j.biochi.2010.02.009, doi:10.1016/j.biochi.2010.02.009. This article has 114 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.biochi.2010.02.009)

[6. (Chen1998Crystal) Xiaomin Chen, Uwe Vinkemeier, Yanxiang Zhao, David Jeruzalmi, James E. Darnell, and John Kuriyan. Crystal structure of a tyrosine phosphorylated stat-1 dimer bound to dna. Cell, 93(5):827–839, May 1998. URL: http://dx.doi.org/10.1016/s0092-8674(00)81443-9, doi:10.1016/s0092-8674(00)81443-9. This article has 559 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/s0092-8674(00)81443-9)

[7. (Zhang2021Clinical) Wenjing Zhang, Xuemei Chen, Guodong Gao, Shubin Xing, Lina Zhou, Xuemei Tang, Xiaodong Zhao, and Yunfei An. Clinical relevance of gain- and loss-of-function germline mutations in stat1: a systematic review. Frontiers in Immunology, March 2021. URL: http://dx.doi.org/10.3389/fimmu.2021.654406, doi:10.3389/fimmu.2021.654406. This article has 44 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fimmu.2021.654406)

[8. (Grönholm2012Structurefunction) Juha Grönholm, Sari Vanhatupa, Daniela Ungureanu, Jouni Väliaho, Tuomo Laitinen, Jarkko Valjakka, and Olli Silvennoinen. Structure-function analysis indicates that sumoylation modulates dna-binding activity of stat1. BMC Biochemistry, October 2012. URL: http://dx.doi.org/10.1186/1471-2091-13-20, doi:10.1186/1471-2091-13-20. This article has 23 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/1471-2091-13-20)

[9. (Vinkemeier1996DNA) U. Vinkemeier, S. L. Cohen, I. Moarefi, B. T. Chait, J. Kuriyan, and J. E. Darnell. Dna binding of in vitro activated stat1 alpha, stat1 beta and truncated stat1: interaction between nh2-terminal domains stabilizes binding of two dimers to tandem dna sites. The EMBO Journal, 15(20):5616–5626, October 1996. URL: http://dx.doi.org/10.1002/j.1460-2075.1996.tb00946.x, doi:10.1002/j.1460-2075.1996.tb00946.x. This article has 235 citations.](https://doi.org/10.1002/j.1460-2075.1996.tb00946.x)

[10. (Shuai2000Modulation) K Shuai. Modulation of stat signaling by stat-interacting proteins. Oncogene, 19(21):2638–2644, May 2000. URL: http://dx.doi.org/10.1038/sj.onc.1203522, doi:10.1038/sj.onc.1203522. This article has 283 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/sj.onc.1203522)

[11. (Vidal2002Stat1Vitamin) Marcos Vidal, Chilakamarti V. Ramana, and Adriana S. Dusso. Stat1-vitamin d receptor interactions antagonize 1,25-dihydroxyvitamin d transcriptional activity and enhance stat1-mediated transcription. Molecular and Cellular Biology, 22(8):2777–2787, April 2002. URL: http://dx.doi.org/10.1128/mcb.22.8.2777-2787.2002, doi:10.1128/mcb.22.8.2777-2787.2002. This article has 115 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.22.8.2777-2787.2002)

[12. (Stark1998HOW) George R. Stark, Ian M. Kerr, Bryan R. G. Williams, Robert H. Silverman, and Robert D. Schreiber. How cells respond to interferons. Annual Review of Biochemistry, 67(1):227–264, June 1998. URL: http://dx.doi.org/10.1146/annurev.biochem.67.1.227, doi:10.1146/annurev.biochem.67.1.227. This article has 3119 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1146/annurev.biochem.67.1.227)

[13. (Ott2023JAKs) Nils Ott, Laura Faletti, Maximilian Heeg, Virginia Andreani, and Bodo Grimbacher. Jaks and stats from a clinical perspective: loss-of-function mutations, gain-of-function mutations, and their multidimensional consequences. Journal of Clinical Immunology, 43(6):1326–1359, May 2023. URL: http://dx.doi.org/10.1007/s10875-023-01483-x, doi:10.1007/s10875-023-01483-x. This article has 22 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1007/s10875-023-01483-x)

[14. (Vidy2005Rabies) Aurore Vidy, Mounira Chelbi-Alix, and Danielle Blondel. Rabies virus p protein interacts with stat1 and inhibits interferon signal transduction pathways. Journal of Virology, 79(22):14411–14420, November 2005. URL: http://dx.doi.org/10.1128/jvi.79.22.14411-14420.2005, doi:10.1128/jvi.79.22.14411-14420.2005. This article has 178 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/jvi.79.22.14411-14420.2005)